Compare Salesforce Inc (CRM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Twist Bioscience Corp — how do they compare? Salesforce Inc trades at $168.39 (market cap $137.23B), while Twist Bioscience Corp trades at $92.62 (market cap $5.77B). The key difference: Salesforce Inc is far larger — about 23.8× Twist Bioscience Corp's market cap, and Salesforce Inc pays a 1.05% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| CRM | TWST | |
|---|---|---|
Market Cap | $137.23B | $5.77B |
Sector | Technology | Health |
52-Week High | $270.25 | $102.88 |
52-Week Low | $150.12 | $24.16 |
Enterprise Value | $167.28B | $5.69B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $171.22, up 4.84% today, showing strong momentum despite recent sector volatility. The stock demonstrates robust fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs. $3.13 expected), impressive 77.64% gross margins, and accelerating revenue growth to $37.9B in 2025. Technical indicators show bullish momentum with the current price near pivot point resistance at $170, while analyst consensus remains strongly positive with a $235.90 price target.
The outlook remains favorable given Salesforce's dominant market position, AI-driven growth initiatives, and improving profitability. Key risks include sector-wide software selloffs, AI competition, and macroeconomic sensitivity. With 76.84% analyst buy ratings and strong institutional support, the stock appears undervalued relative to growth prospects despite near-term volatility concerns.
TWST trades at $90.35, down 0.31% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels near key support at $89. Revenue growth remains strong, reaching $376.57M in 2025, though the company continues to report net losses. Recent news highlights AI-driven drug discovery collaborations and insider selling activity, while analyst consensus leans bullish with a $91.63 price target.
The stock offers growth exposure to synthetic biology and AI-enabled therapeutics, but carries significant risk due to persistent negative cash flow and profitability challenges. Investor sentiment is cautiously optimistic, balancing innovation potential against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
